Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the end of March.